HibMenCY-TT + DTaP-HBV-IPV vaccinees were re-randomized ( 2:2:1 ) to receive MenACWY-TT at 12-15 months and DTaP at 15-18 months ( MenACWY-TT group ) ; MenACWY-TT co-administered with DTaP at 15-18 months ( Coad group ) ; or HibMenCY-TT at 12-15 months and DTaP at 15-18 months ( HibMenCY-TT group ) .